Table 4. Haplotype analysis for the eNOS 894G>T, miR-499b A>G, and TNF-α-863C>A polymorphisms in RPL patients and controls.
| Haplotype | Controls (2n = 100) | RPL patients (2n = 106) | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| eNOS/miR-449b/TNF-α | |||||
| G-A-C | 58 (58.0) | 51 (48.1) | 1.00 | ||
| G-A-A | 14 (14.0) | 12 (11.3) | 0.97 (0.41–2.30) | 0.954 | |
| G-G-C | 22 (22.0) | 22 (20.8) | 1.14 (0.56–2.29) | 0.719 | |
| G-G-A | 0 (0.0) | 8 (7.5) | 19.31 (1.09–342.87) | 0.044* | |
| T-A-C | 3 (3.0) | 7 (6.6) | 2.65 (0.65–10.80) | 0.173 | |
| T-A-A | 1 (1.0) | 2 (1.9) | 2.27 (0.20–25.83) | 0.507 | |
| T-G-C | 2 (2.0) | 2 (1.9) | 1.14 (0.15–8.37) | 0.900 | |
| T-G-A | 0 | 2 (1.9) | 5.68 (0.27–121.06) | 0.266 | |
| eNOS/miR-449b | |||||
| G-A | 72 (72.0) | 63 (59.4) | 1.00 | ||
| G-G | 22 (22.0) | 31 (29.2) | 1.61 (0.85–3.06) | 0.146 | |
| T-A | 4 (4.0) | 9 (8.5) | 2.57 (0.76–8.76) | 0.131 | |
| T-G | 2 (2.0) | 3 (2.8) | 1.71 (0.28–10.59) | 0.562 | |
| eNOS/TNF-α | |||||
| G-C | 80 (80.0) | 74 (69.8) | 1.00 | ||
| G-A | 14 (14.0) | 20 (18.9) | 1.54 (0.73–3.28) | 0.258 | |
| T-C | 5 (5.0) | 8 (7.5) | 1.73 (0.54–5.52) | 0.355 | |
| T-A | 1 (1.0) | 4 (3.8) | 4.32 (0.47–39.58) | 0.195 | |
| miR-449b/TNF-α | |||||
| A-C | 61 (61.0) | 58 (54.7) | 1.00 | ||
| A-A | 24 (24.0) | 24 (22.6) | 1.05 (0.54–2.06) | 0.883 | |
| G-C | 15 (15.0) | 14 (13.2) | 0.98 (0.44–2.21) | 0.964 | |
| G-A | 0 (0.0) | 10 (9.4) | 22.08 (1.26–385.34) | 0.034* | |
Values are presented as number (%) of cases.
eNOS = endothelial nitric oxide synthase, TNF = tumor necrosis factor, RPL = recurrent pregnancy loss, OR = odds ratio, CI = confidence interval.
*P < 0.05.